Recently, an open-label, single-arm phase I/II clinical trial (ChiCTR2000033567) enrolled 50 MM patients, who were treated with BCMA/CD19 dual-targeted CAR-T cells. The gene discussed is CD19; the disease is Miyoshi myopathy.